Enfortumab Vedotin (Padcev™) | AGS-22M6E | Clinical Trials

 

TrialTitleStudy Record DetailPhaseSponsor/Colaborator
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4NCT01409135 IAgensys, Inc./Seattle Genetics, Inc.
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4NCT02091999IAgensys, Inc./Seattle Genetics, Inc
A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial CarcinomaNCT03070990 IAgensys, Inc./Seattle Genetics, Inc
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103)NCT03288545Agensys, Inc./Seattle Genetics, Inc
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201) NCT03219333IIAgensys, Inc./Seattle Genetics, Inc
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC) NCT03869190I/IIHoffmann-La Roche

Collaborators: Forty Seven Inc.,Tesaro Inc., Seattle Genetics and Astellas Inc., Sanofi

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)NCT03474107IIIAgensys, Inc./Seattle Genetics, Inc
An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial CarcinomaNCT04136808Agensys, Inc./Seattle Genetics, Inc

Last Editorial Review: December 20, 2019